Neuroinflammation is a significant component of Alzheimer disease (AD). Our data demonstrated
compromised regulatory T cells (Tregs) phenotype and suppressive function in AD patients,
skewing the immune system toward a proinflammatory status and potentially contributing in
disease progression. Low dose interleukin-2 (IL-2) is now viewed as a very promising
immunoregulatory drug having the capacity to selectively expand and restore functional Tregs.
This study is a phase I open-label study to assess subcutaneous interleukin-2 (IL2) safety
and potential efficacy as a Treg inducer in AD. 8 Alzheimer dementia patients with mild
clinical dementia will be recruited into the study. The baseline cognitive status will be
evaluated in these patients. Monthly five-day-courses of subcutaneous IL2 (1MUI/day) will be
administered for a total of 4 months. Changes in Tregs from pre to post injections will be
measured during the study period. The expected time participants will be in the study is 6
months.